(Yicai Global) April 28 -- Guangzhou Wondfo Biotech is “surprised and disappointed” by the Indian Council of Medical Research’s decision to stop using its rapid antibody Covid-19 testing kits, the supplier said today.

“The Wondfo SARS-CoV-2 Antibody Test (Lateral Flow Method) is one of the first tests to receive an import license from India, and has been validated and approved by the ICMR through National Institute of Virology, Pune,” Wondfo said in a statement today, maintaining confidence in the quality of products.

The ICMR advised Indian states to stop using the kits, as well as those procured from Zhuhai Livzon Diagnostics, and return them to suppliers yesterday, saying “the results have shown wide variation in their sensitivity, despite early promise of good performance for surveillance purposes.”

The use of appropriate and pertinent testing methods varies over the course of viral infection, Wondfo added, saying it is investigating the ICMR’s concerns with the products.

Editor: James Boynton